On October 31, 2022, before market hours, Instil Bio issued a press release entitled “Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing” which announced the pause and that the pause was due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.” Further, the Company announced that “[a]lthough no manufacturing failures have been observed to date in the ongoing Phase 1 trial of ITIL-306, the Company has also voluntarily paused enrollment in this trial as part of its overall manufacturing analysis.” The Company also announced that it “intends to provide an update on the manufacturing analysis by early Q1 2023.”
On this news, Instil Bio’s stock fell $1.95 per share, or 37%, to close at $3.30 per on October 31, 2022.